{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:30:26Z","timestamp":1786350626406,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09810-1","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:08:49Z","timestamp":1786345729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-9897","authenticated-orcid":false,"given":"Asma","family":"Rasouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-6207","authenticated-orcid":false,"given":"Masoud","family":"Khalifezadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"11","key":"9810_CR1","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"9810_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"9810_CR3","unstructured":"Mirza HA, Saleh HM. Generalized Pustular Psoriasis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"issue":"6","key":"9810_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384.","journal-title":"Int J Dermatol"},{"issue":"3","key":"9810_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1525-1470.2009.00918.x","volume":"26","author":"PH Chao","year":"2009","unstructured":"Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352\u20134.","journal-title":"Pediatr Dermatol"},{"key":"9810_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12703\/r\/10-62","volume":"10","author":"AMG Brunasso","year":"2021","unstructured":"Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62.","journal-title":"Fac Rev"},{"issue":"3","key":"9810_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2020","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355\u201370.","journal-title":"Am J Clin Dermatol"},{"key":"9810_CR8","unstructured":"Shah M, Al Aboud DM, Crane JS, Kumar S. Pustular Psoriasis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"issue":"10","key":"9810_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/exd.13699","volume":"27","author":"A Boehner","year":"2018","unstructured":"Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067\u201377.","journal-title":"Exp Dermatol"},{"issue":"2","key":"9810_CR10","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.jisp.2018.09.008","volume":"19","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Xu JH. Investigation of psoriasis susceptibility loci in psoriatic arthritis and a generalized pustular psoriasis cohort. J Investig Dermatol Symp Proc. 2018;19(2):S83-s5.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"9810_CR11","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"9810_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","volume":"139","author":"B Meier-Schiesser","year":"2019","unstructured":"Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, et al. Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. J Invest Dermatol. 2019;139(4):848\u201358.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"9810_CR13","first-page":"582","volume":"49","author":"ZT Li","year":"2018","unstructured":"Li ZT, Wang S. [Genetic Polymorphism of IL36RN in Han Patients with Generalized Pustular Psoriasis Alone in Sichuan Region]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018;49(4):582\u20136.","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"issue":"1","key":"9810_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.25259\/IJDVL_542_2022","volume":"90","author":"B Vasudevan","year":"2023","unstructured":"Vasudevan B, Das P, Bhatt S. Pustular psoriasis: A distinct aetiopathogenic and clinical entity. Indian J Dermatol Venereol Leprol. 2023;90(1):19\u201329.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"9810_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13555-022-00881-0","volume":"13","author":"R Rivera-D\u00edaz","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatol Ther (Heidelb). 2023;13(3):673\u201388.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"9810_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40265-023-01988-0","volume":"84","author":"D Bernardo","year":"2024","unstructured":"Bernardo D, Tha\u00e7i D, Torres T. Spesolimab for the Treatment of Generalized Pustular Psoriasis. Drugs. 2024;84(1):45\u201358.","journal-title":"Drugs"},{"key":"9810_CR17","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.2147\/IDR.S421299","volume":"16","author":"Q Xu","year":"2023","unstructured":"Xu Q, Wang X, Yang A, Wei G. Refractory palmoplantar pustulosis successfully treated with JAK inhibitor tofacitinib: a case series. Infect Drug Resist. 2023;16:5165\u201372.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"9810_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1346-8138.17570","volume":"52","author":"Y Tada","year":"2025","unstructured":"Tada Y, Armstrong AW, Imafuku S, Okubo Y, Morita A, Zhong Y, et al. Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study. J Dermatol. 2025;52(2):353\u20138.","journal-title":"J Dermatol"},{"key":"9810_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"9810_CR20","unstructured":"National Heart L, and Blood Institute. Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group. 2014."},{"key":"9810_CR21","unstructured":"National Heart L, and Blood Institute. Quality Assessment Tool for Observational CohortCross-Sectional Studies. 2014."},{"issue":"2","key":"9810_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133.","journal-title":"BMJ Evid Based Med"},{"key":"9810_CR23","doi-asserted-by":"publisher","first-page":"adv44083","DOI":"10.2340\/actadv.v105.44083","volume":"105","author":"S Lyu","year":"2025","unstructured":"Lyu S, Xue X, Wang N, Liu H, Zhang F. Efficacy and Safety of Tofacitinib in Palmoplantar Pustulosis: A Retrospective Study. Acta Derm Venereol. 2025;105:adv44083.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"9810_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.25259\/IJDVL_751_2024","volume":"91","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Zhang X, Wang H, Yang R, Luo S. Clinical efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis: A single-center retrospective study. Indian J Dermatol Venereol Leprol. 2025;91(4):540\u20133.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"9810_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40257-025-00971-7","volume":"26","author":"D Huang","year":"2025","unstructured":"Huang D, Jiang X, Yang N, Wang Y, Li Y, Yi X, et al. Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study. Am J Clin Dermatol. 2025;26(5):843\u201350.","journal-title":"Am J Clin Dermatol"},{"key":"9810_CR26","unstructured":"Zhang X, Luo S. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis. Chin J Dermatology. 2025."},{"key":"9810_CR27","doi-asserted-by":"crossref","unstructured":"Gleeson D, Chapman S, McAteer H, Qin A, Gregory J, Pizzato J et al. Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol. BMJ Open. 2025;15(8).","DOI":"10.1136\/bmjopen-2025-106361"},{"issue":"S1","key":"9810_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ajd.14497","volume":"66","author":"B Hu","year":"2025","unstructured":"Hu B, Lai F, Lee S. Biologics\/Psoriasis. Australas J Dermatol. 2025;66(S1):18\u201330.","journal-title":"Australas J Dermatol"},{"issue":"12","key":"9810_CR29","first-page":"1591","volume":"23","author":"N Cramer","year":"2025","unstructured":"Cramer N, Wellmann P, Schon MP, Mossner R. Successful treatment of palmoplantar pustulosis with topical ruxolitinib. JDDG J Dtsch Dermatol Ges. 2025;23(12):1591\u20133.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"4","key":"9810_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000544921","volume":"11","author":"BY Dong","year":"2025","unstructured":"Dong BY, Meng FZ, Wei JN, Lin ZM, Li WZ, Li C, et al. Palmoplantar pustulosis during pregnancy was successfully treated with tofacitinib: a case report. Skin Appendage Disord. 2025;11(4):335\u20138.","journal-title":"Skin Appendage Disord"},{"key":"9810_CR31","doi-asserted-by":"crossref","unstructured":"Yang BY, Yu HX, Yao W, Wang HY. Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib. Front Immunol. 2025;16.","DOI":"10.3389\/fimmu.2025.1476584"},{"key":"9810_CR32","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang M, He M, Tang T. Case report: Efficacy of tofacitinib in the treatment of generalized pustular psoriasis. Front Med. 2025;12.","DOI":"10.3389\/fmed.2025.1518583"},{"issue":"2","key":"9810_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/ced\/llad341","volume":"49","author":"X Wang","year":"2024","unstructured":"Wang X, Yan X, Zang X, Yang Q. A case of refractory generalized pustular psoriasis treated with upadacitinib. Clin Exp Dermatol. 2024;49(2):170\u20132.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"9810_CR34","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/RHU.0000000000002104","volume":"30","author":"Y Taniguchi","year":"2024","unstructured":"Taniguchi Y, Yamamoto H. Therapeutic Potential of Janus Kinase Inhibitors for Treating Palmoplantar Pustulosis\/Pustulotic Arthro-osteitis. J Clin Rheumatol. 2024;30(6):e157.","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"9810_CR35","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s12098-024-05214-x","volume":"91","author":"P Xiaoyuan","year":"2024","unstructured":"Xiaoyuan P, Lin S, Xinyu Z, Qianya S, Mei C, Fei W, Zhengbang D. Successful Treatment of Generalized Pustular Psoriasis Coexisting with Pityriasis Rubra Pilaris with Upadacitinib. Indian J Pediatr. 2024;91(12):1296.","journal-title":"Indian J Pediatr"},{"issue":"1","key":"9810_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/ds.DS-D-23-00156","volume":"42","author":"M Ma","year":"2024","unstructured":"Ma M, Qian T, Li C. A young woman with generalized pustular psoriasis and synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated successfully with upadacitinib. Dermatol Sin. 2024;42(1):72\u20133.","journal-title":"Dermatol Sin"},{"issue":"5","key":"9810_CR37","doi-asserted-by":"publisher","first-page":"668","DOI":"10.25259\/IJDVL_884_2023","volume":"90","author":"X Li","year":"2024","unstructured":"Li X, Liu G, Chen S, Liu Y. A case of palmoplantar pustulosis with atopic dermatitis: Baricitinib is a safe and effective treatment. Indian J Dermatol Venereol Leprol. 2024;90(5):668\u201370.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"9810_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","volume":"51","author":"S Imafuku","year":"2024","unstructured":"Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024;51(3):365\u201379.","journal-title":"J Dermatol"},{"issue":"5","key":"9810_CR39","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1111\/1346-8138.17046","volume":"51","author":"W Hu","year":"2024","unstructured":"Hu W, Wang Y, Zhang S, Wu X, Lian C. Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases. J Dermatol. 2024;51(5):e151\u20133.","journal-title":"J Dermatol"},{"key":"9810_CR40","doi-asserted-by":"crossref","unstructured":"Du N, Yang J, Zhang Y, Lv X, Cao L, Min W. Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients. Front Med. 2024;11.","DOI":"10.3389\/fmed.2024.1476793"},{"issue":"1","key":"9810_CR41","doi-asserted-by":"publisher","first-page":"2399220","DOI":"10.1080\/09546634.2024.2399220","volume":"35","author":"DA De Luca","year":"2024","unstructured":"De Luca DA, Papara C, Hawro T, Thaci D, Stander S. Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis. J Dermatol Treat. 2024;35(1):2399220.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"9810_CR42","doi-asserted-by":"publisher","first-page":"2280508","DOI":"10.1080\/09546634.2023.2280508","volume":"34","author":"ZY Zhang","year":"2023","unstructured":"Zhang ZY, Mi WY, Wang YY, Li W. Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib. J Dermatolog Treat. 2023;34(1):2280508.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"9810_CR43","first-page":"280","volume":"21","author":"J Mohr","year":"2023","unstructured":"Mohr J, Rahbar Kooybaran N, Sch\u00f6n MP, M\u00f6ssner R. Response of palmoplantar pustulosis to upadacitinib. JDDG J Dtsch Dermatol Ges. 2023;21(3):280\u20132.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"9810_CR44","unstructured":"Kooybaran NR, Tsianakas A, Assaf K, Mohr J, Wilsmann-Theis D, Moessner R. Response of palmoplantar pustulosis to upadacitinib: A case series of five patients. J Der Deutschen Dermatologischen Gesellschaft. 2023:6."},{"issue":"12","key":"9810_CR45","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1111\/1346-8138.16901","volume":"50","author":"N Ikumi","year":"2023","unstructured":"Ikumi N, Fujita H, Wada TT. Generalized pustular psoriasis occurred immediately after the withdrawal of upadacitinib in a patient with plaque psoriasis with inflammatory arthritis. J Dermatol. 2023;50(12):e398\u20139.","journal-title":"J Dermatol"},{"issue":"4","key":"9810_CR46","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/ajd.14142","volume":"64","author":"FM Gaiani","year":"2023","unstructured":"Gaiani FM, Malagoli P, Carrera CG. Palmoplantar pustulosis successfully treated with upadacitinib: report of three cases. Australas J Dermatol. 2023;64(4):568\u201370.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"9810_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamadermatol.2020.3095","volume":"157","author":"C Li","year":"2021","unstructured":"Li C, Li Z, Cao Y, Li L, Li F, Li Y, et al. Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome. JAMA Dermatology. 2021;157(1):74\u20138.","journal-title":"JAMA Dermatology"},{"issue":"4","key":"9810_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13753","volume":"33","author":"R M\u00f6ssner","year":"2020","unstructured":"M\u00f6ssner R, Hoff P, Mohr J, Wilsmann-Theis D. Successful therapy of palmoplantar pustulosis with tofacitinib-report on three cases. Dermatol Ther. 2020;33(4):e13753.","journal-title":"Dermatol Ther"},{"issue":"1","key":"9810_CR49","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1111\/ajd.13117","volume":"61","author":"D Haynes","year":"2020","unstructured":"Haynes D, Topham C, Hagstrom E, Greiling T. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report. Australas J Dermatol. 2020;61(1):e108\u201310.","journal-title":"Australas J Dermatol"},{"key":"9810_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clim.2016.10.003","volume":"173","author":"T Koga","year":"2016","unstructured":"Koga T, Sato T, Umeda M, Fukui S, Horai Y, Kawashiri SY, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147\u20138.","journal-title":"Clin Immunol"},{"key":"9810_CR51","first-page":"S7","volume":"146","author":"F Juliane","year":"2016","unstructured":"Juliane F, Markus S. Immediate response of therapy-refractory palmoplantar pustular psoriasis and psoriasis arthritis to tofacitinib. Swiss Med Wkly. 2016;146:S7\u2013S.","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"9810_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/bjd\/ljac130","volume":"188","author":"D Gleeson","year":"2023","unstructured":"Gleeson D, Barker J, Capon F, Pink AE, Woolf RT, Smith CH, et al. Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic. Br J Dermatol. 2023;188(4):471\u20133.","journal-title":"Br J Dermatol"},{"key":"9810_CR53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/CCID.S494567","volume":"18","author":"Q Gu","year":"2025","unstructured":"Gu Q, Zhang C, Lin Z, Fu Y, Li C, Ying Z. Short-Term Relief with Upadacitinib: A Case Report of Palmoplantar Pustulosis in a Pediatric Patient. Clin Cosmet Investig Dermatol. 2025;18:797\u2013800.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"9810_CR54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/CCID.S517299","volume":"18","author":"Z Yang","year":"2025","unstructured":"Yang Z, Lu J, Li Z. Abrocitinib treatment for localized type of generalized pustular psoriasis: a case report. Clin Cosmet Investig Dermatol. 2025;18:663\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"9810_CR55","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","volume":"37","author":"SH Kardaun","year":"2010","unstructured":"Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol. 2010;37(12):1220\u20139.","journal-title":"J Cutan Pathol"},{"issue":"12","key":"9810_CR56","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/biomedicines9121746","volume":"9","author":"G Genovese","year":"2021","unstructured":"Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12):1746.","journal-title":"Biomedicines"},{"issue":"11","key":"9810_CR57","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2014.156","volume":"10","author":"D Dietrich","year":"2014","unstructured":"Dietrich D, Gabay C, Inflammation. IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol. 2014;10(11):639\u201340.","journal-title":"Nat Rev Rheumatol"},{"key":"9810_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111435","volume":"127","author":"A Heidari","year":"2024","unstructured":"Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment. Int Immunopharmacol. 2024;127:111435.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"9810_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"key":"9810_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jare.2024.06.013","volume":"71","author":"X Meng","year":"2025","unstructured":"Meng X, Zhong Y, Kuang X, Zhang Y, Yang L, Cai Y, et al. Targeting the STAT3\/IL-36G signaling pathway can be a promising approach to treat rosacea. J Adv Res. 2025;71:429\u201340.","journal-title":"J Adv Res"},{"key":"9810_CR62","first-page":"33","volume":"13","author":"K Heidemeyer","year":"2023","unstructured":"Heidemeyer K, May Lee M, Cazzaniga S, Yawalkar N, Naldi L. Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies. Psoriasis (Auckl). 2023;13:33\u201358.","journal-title":"Psoriasis (Auckl)"},{"issue":"10","key":"9810_CR63","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.4103\/jfmpc.jfmpc_112_24","volume":"13","author":"A Beard","year":"2024","unstructured":"Beard A, Trotter SC. JAK 1\u20133 inhibitors and TYK-2 inhibitors in dermatology: practical pearls for the primary care physician. J Fam Med Prim Care. 2024;13(10):4128\u201334.","journal-title":"J Fam Med Prim Care"},{"issue":"9","key":"9810_CR64","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.3390\/ijms25094681","volume":"25","author":"AR Furtunescu","year":"2024","unstructured":"Furtunescu AR, Georgescu SR, Tampa M, Matei C. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature. Int J Mol Sci. 2024;25(9):4681.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"9810_CR65","doi-asserted-by":"publisher","first-page":"e42084","DOI":"10.1016\/j.heliyon.2025.e42084","volume":"11","author":"J Wang","year":"2025","unstructured":"Wang J, Ma T, Sun X, Liu L, Hong S, Cha H, et al. Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022. Heliyon. 2025;11(3):e42084.","journal-title":"Heliyon"},{"issue":"11","key":"9810_CR66","first-page":"1387","volume":"21","author":"N Rahbar Kooybaran","year":"2023","unstructured":"Rahbar Kooybaran N, Tsianakas A, Assaf K, Mohr J, Wilsmann-Theis D, Mossner R. Response of palmoplantar pustulosis to upadacitinib: a case series of five patients. JDDG J Dtsch Dermatol Ges. 2023;21(11):1387\u201392.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"9810_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1476584","volume":"16","author":"B Yang","year":"2025","unstructured":"Yang B, Yu H, Yao W, Wang H. Case report: successful management of refractory palmoplantar pustulosis with upadacitinib. Front Immunol. 2025;16:1476584.","journal-title":"Front Immunol"},{"key":"9810_CR68","doi-asserted-by":"publisher","first-page":"1518583","DOI":"10.3389\/fmed.2025.1518583","volume":"12","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang M, He M, Tang T. Case report: Efficacy of tofacitinib in the treatment of generalized pustular psoriasis. Front Med (Lausanne). 2025;12:1518583.","journal-title":"Front Med (Lausanne)"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09810-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:02:31Z","timestamp":1786348951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9810"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09810-1","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}